Key clinical point: T-DSM1 had similar efficacy, less toxicity vs. standard chemotherapy for HER2- and HR-positive breast cancer.
Major finding: The pCR rates were 45% and 47% with T-DM1 and DTP, respectively.
Study details: The phase 2 PREDIX HER2 trial of 199 patients.
Disclosures: Dr. Bergh reported a financial relationship with UpToDate, and research funding to his institution from Amgen, AstraZeneca, Bayer, Merck, Pfizer, Roche, and Sanofi.
Bergh J et al. ASCO 2019, Abstract 501.